In vivo pharmacokinetic studies in CD rats revealed that racemic Integrin-IN-2 (compound 39) has a low plasma clearance of 8 mL/(min kg), a low to moderate volume of distribution of 0.5 L/kg, a moderate halflife of 1.8 h, and very high bioavailability of 98%.